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Abstract
Extraskeletal myxoid chondrosarcoma is a rare form of malignant mesenchymal neoplasm mainly localized into the limbs,
particularly in the thigh and popliteal fossa. It has been classified as a low-grade sarcoma so far, but it shows a tendency to
relapse and metastasize. In the early stage of disease, surgery represents the only chance of cure. In case of diffuse metastatic
disease, systemic chemotherapy with anthracyclines is the standard of care. In this paper, we present a case of a patient
affected by this rare disease and the analysis of radiological, surgical and histopathological aspects.
INTRODUCTION
Extraskeletal myxoid chondrosarcoma (EMC) is a form of
sarcoma mainly localized into the limbs [1]. Firstly described
by Stout et al., it has been classified as low-grade soft tissue
sarcoma with uncertain differentiation by the World Health
Organization Classification of Tumors of Soft Tissue and Bone. It
is distinguished from other sarcomas by its unique histology and
characteristic chromosomal translocation, typically t (9, 22)(q22;
q12.2) and the EWSR1/NR4A3 fusion [1–4]. This tumor is rare and
its prevalence is around 1/1000 000 people. Myxoid chondrosar-
coma shows an indolent behavior but, after a long-term follow-
up, local and distant progressions of disease are demonstrated
in more than 40% of patients with a 10 years survival of 65–88%
[4–6]. The most common site of distant metastases is the
lung, but soft tissues and lymph nodes also can be involved
[1, 5, 7]. To treat distant metastatic disease or local recurrence,
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surgery, radiotherapy and/or systemic chemotherapy have been
proposed [6–9]. For patients who have chondrosarcoma in
the unresectable setting, antiangiogenic agents are reportedly
effective.
CASE PRESENTATION
The patient, a 55-year-old woman, has been complaining of
vague abdominal pain and severe constipation lasting for
3 months. She was admitted to the gynecological depart-
ment, where an abdominal ultrasound scan was made and
showed a large mass of 10 centimeters in the retroperitoneal
space. After this evaluation, computed tomography (CT) scan
and a magnetic resonance (MR) were performed. Laboratory
tests were not suggestive for tumoral disease, being neo-







/jscr/article/2020/12/rjaa503/6053184 by guest on 11 January 2021
2 S. Bacchetti et al.
Figure 1: Multidetector computed tomography appearance of the lesions. Coronal multiplanar reformation (A) of the portal venous phase scan shows two
different left-sided solid hypoattenuating masses located in the pelvis (arrow) and intermuscular space between the gluteus medius muscle and gluteus minimus
muscle (arrowhaed). Progressive, slow and inhomogeneous contrast-enhancement occurred (B), as better appreciated in the transverse image acquired in the
delayed phase.
Concerning imaging description, the preliminary 64-raw
MD-CT (Fig. 1) found a left-sided solid hypoattenuating, well-
defined pelvic mass, with poor and inhomogeneous contrast
enhancement. A similar mass coexisted in the intermuscular
space between left gluteus medius and gluteus minimus.
On 1.5T MR (Fig. 2), masses were slight hypointense as
compared to muscle on T1-weighted imaging, with sparse
hyperintense foci suggesting the presence of hemorrhage,
especially in the pelvic one. Signal intensity was predominantly
slightly higher than fat on T2-weighted images, with internal
low-signal septa, showing restricted diffusion and minimal
contrast-enhancement. The hyperintense component was
characterized by inhomogeneous contrast enhancement. Of
note, there was some asymmetry between the lesions, with
the pelvic one showing more inhomogeneity on T2-weighted
imaging and less intense contrast-enhancement as compared
to the extrapelvic one. Overall, MR findings were in line with
previously reported findings [5]. At radiological scans, no distant
metastases were documented in the liver or lungs.
No preoperative bioptical samples were performed and, fol-
lowing a multidisciplinary oncological meeting, the patient was
planned for surgical procedure.
Being this sarcoma localized in two different sites, pelvic-
retroperitoneal and gluteal, the operation was carried on in
two surgical steps. After median laparotomy, in the left pelvic
region, a mass of about 10 centimeters of maximum diameter,
dislocating the bladder anteriorly, the left iliac vessels cranially
and medially the sigma, was documented. Dissection and
isolation of the mass from the surrounding structures were
completed. A specimen of the mass capsule and myxoid material
resulted to be a malignant mesenchymal neoplasia with a
myxoid appearance. The mass was removed with radical intent.
After its complete clearance, the entire surgical field was treated
with argon-laser electrofulguration and, immediately after, with
a peritoneal extensive lavage (according to Kuramoto technique)
[10]. At the end of this surgical procedure, the operation was con-
sidered R0. Therefore, the patient was placed on the right flank
position. An incision of the left buttock region was made, and,
Deeping within the muscle planes, a lobulated mass of about 8
centimeters in diameter was found. After its complete removal,
an argon-laser electrofulguration of the entire surgical area was
applied. Two different surgical specimens were analyzed by the
histopathological laboratory, labeled retroperitoneal-pelvic and
left buttock (gluteal) tumors. At the gross examination, they
both presented multiple fragments of glistening and gelatinous
tissues with intratumoral hemorrhage, weighting 190 and 144
grams, respectively. Their histological features were comparable
and characterized by multiple lobules with abundant myxoid-
chondromyxoid matrix in which monomorphic cells with
uniform nuclei and eosinophilic cytoplasm connected one
another to form cords, small clusters, and complex trabec-
ular or cribriform structures. No mitotic activity was seen;
diffuse areas of hemorrhage and necrosis were identified
(Fig. 3).
An extensive panel of immunoistochemical markers was
tested in order to better characterize the tumors. The neoplastic
cells stained strongly only for vimentin; they were negative for
epithelial markers (CK AE1/AE3, CK 5/6, CK7, CK19, CK20, EMA,
CAM 5.2, polyclonal CEA), for muscular markers (smooth muscle
actin, desmin, myogenin) and for S-100 protein, SOX10, CD34,
MDM2 and Brachyury.
Considering the morphological features and the immunoisto-
chemical profile, adenocarcinoma, myoepithelial tumors, myx-
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Figure 2: Lesions appearance on MR imaging. On transverse fat-saturated volumetric gradient echo T1-weighted imaging (A) both masses appeared slightly hypointense
compared to muscle, with hyperintense areas in the larger one (arrow) suggesting the presence of haemorrhagic foci. Lesions were hyperintense on transverse turbo
spin-echo T2-weighted imaging (B), in line with the presence of myxoid content, showing inhomogeneous appearance due to low-signal septa showing restricted
diffusion on the apparent diffusion coefficient map (arrow in C). Contrast enhancement was inhomogeneous, as shown in the coronal fat-saturated post-contrast
image (D). Masses showed well-defined margins, with no invasion of the adjacent structures.
Figure 3: Histological picture of the tumor showing clusters and chords of
medium-sized epithelioid cells immersed in a myxoid matrix (H&E, ×100).
were not possible and the final diagnosis of an EMC was estab-
lished.
DISCUSSION AND CONCLUSIONS
This case report is interesting for the rare double site presenta-
tion and for the pelvic localization of myxoid chondrosarcoma.
The surgical workup consisted of two-step complex operations,
in the pelvic area for first and then in the gluteal region. In
both cases, after wide excision (Enneking classification), the
tumor removal was complete. A double physical intraopera-
tive adjuvant treatment, argon-laser electrofulguration of the
entire surgical field and an extensive peritoneal lavage of the
abdominal cavity, was performed. The postoperative course was
uneventful. This case is the base for a multi-institutional phase II
study, which intends to assess the role of adjuvant intraoperative
treatment of sarcoma.





1. Drilon A, Popat S, Bhuchar G, D’Adamo D, Keohan ML,
Fisher C, et al. Extraskeletal myxoid chondrosarcoma: a
retrospective review from 2 referral centers emphasizing
long-term outcomes with surgery and chemotherapy. Cancer
2008;113:3364–71.
2. Stacchiotti S, Ferrari S, Andres Redondo A, Hindi N, Palmerini
E, Vaz Salgado MA, et al. Pazopanib for treatment of
advanced extraskeletal myxoid chondrosarcoma: a mul-
ticentre, single-arm, phase 2 trial. Lancet Oncol Actions
2019;20:1252–62.
3. Tateishi U, Hasegawa T, Nojima T, Takegami T, Arai Y. MRI
features of extraskeletal myxoid chondrosarcoma. Skeletal
Radiol 2006;35:27–33.
4. Meis-Kindblom M, Bergh P, Gunterberg B, Kindblom LG.
Extraskeletal myxoid chondrosarcoma: a reappraisal of its
morphologic spectrum and prognostic factors based on 117
cases. Am J Surg Pathol 1999;23:636–50.
5. Stacchiotti S, Baldi GG, Morosi C, Gronchi A, Maestro R.






/jscr/article/2020/12/rjaa503/6053184 by guest on 11 January 2021
4 S. Bacchetti et al.
current research on biology and clinical management. Can-
cers (Basel) 2020;12:E2703.
6. Masrouha K, Multani I, Bhatt O, Ghert M. Extraskeletal myx-
oid chondrosarcoma: long-term survival in the setting of
metastatic disease. Case Rep Orthop 2020;2:684–746.
7. Basile G, Mattei JC, Alshaygy I, Griffin AM, Catton CN, Chung
PW, et al. Curability of patients with lymph node metastases
from extremity soft-tissue sarcoma. Cancer 2020;1097–142.
8. Wagner MJ, Chau B, Loggers ET, Pollack SM, Kim TS, Kim
EY, et al. Long-term outcomes for extraskeletal myxoid
chondrosarcoma: a SEER database analysis. Cancer Epidemiol
Biomarkers Prev 2020;29:2351–7.
9. Wakely PE Jr. Extraskeletal myxoid chondrosarcoma:
combining cytopathology with molecular testing to
achieve diagnostic accuracy. J Am Soc Cytopathol 2020;31:
S 2213–945.
10. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y,
Matsuda M, et al. Extensive intraoperative peritoneal lavage
as a standard prophylactic strategy for peritoneal recurrence






/jscr/article/2020/12/rjaa503/6053184 by guest on 11 January 2021
